Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$16.61 USD
-0.94 (-5.36%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $16.85 +0.24 (1.44%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CRBP 16.61 -0.94(-5.36%)
Will CRBP be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRBP
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
Other News for CRBP
OrbiMed Advisors LLC Acquires New Stake in Corbus Pharmaceuticals Holdings Inc
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates